论文部分内容阅读
目的探讨环磷酰胺+多柔比星+长春新碱+泼尼松联合化疗(CHOP)方案和氟达拉滨+环磷酰胺+地塞米松联合化疗(FCD)方案治疗初治惰性淋巴瘤的疗效和安全性。方法回顾性分析江门市新会人民医院2012年4月—2015年4月入院的50例行初治惰性淋巴瘤治疗的患者临床资料,按治疗方案的不同分为两组,每组25例。CHOP组患者给予环磷酰胺+多柔比星+长春新碱+泼尼松联合化疗(CHOP方案),FCD组患者给予氟达拉滨+环磷酰胺+地塞米松联合化疗(FCD方案),比较两组患者治疗效果及骨髓抑制情况等。组间率的比较采用χ2检验。结果 CHOP组治疗后病情完全缓解(CR)5例、部分缓解(PR)4例、稳定(SD)8例、进展(PD)5例,有效率36.00%(9/25);对照组分别为2、3、8、8例和20.00%(5/25),差异无统计学意义(P>0.05)。CHOP组患者骨髓抑制Ⅲ~Ⅳ度情况及骨髓总抑制情况均低于FCD组患者,差异有统计学意义(P<0.01)。结论 CHOP方案与FCD方案对初治惰性淋巴瘤的治疗效果无显著性差异,但FCD组患者骨髓抑制情况明显增强。
Objective To investigate the effect of cyclophosphamide + doxorubicin + vincristine + prednisone combined with chemotherapy (CHOP) and fludarabine + cyclophosphamide + dexamethasone combined with chemotherapy (FCD) in the treatment of idiopathic indolent lymphoma Efficacy and safety. Methods The clinical data of 50 patients with newly diagnosed idiopathic lymphoma who were admitted to Xinhui Peoples Hospital of Jiangmen City from April 2012 to April 2015 were retrospectively analyzed. According to the different treatment plans, they were divided into two groups of 25 cases each. Patients in the CHOP group were treated with cyclophosphamide plus doxorubicin plus vincristine plus prednisone in combination with chemotherapy (CHOP regimen). Patients in the FCD group were treated with fludarabine + cyclophosphamide plus dexamethasone in combination with chemotherapy (FCD regimen) Comparison of two groups of patients with treatment and bone marrow suppression and so on. Comparison of rates between groups using χ2 test. Results In CHOP group, there were 5 patients with complete remission (CR), 4 with partial remission (PR), 8 with stable (SD) and 5 with progressive (PD). The effective rate was 36.00% (9/25) 2, 3, 8, 8 cases and 20.00% (5/25), the difference was not statistically significant (P> 0.05). The level of Ⅲ ~ Ⅳ myelosuppression and total bone marrow suppression in patients with CHOP were lower than those in patients with FCD, the difference was statistically significant (P <0.01). Conclusion There is no significant difference between CHOP and FCD in the treatment of idiopathic indolent lymphoma, but the bone marrow suppression in patients with FCD is significantly increased.